Top Bucket AI

About

Krishnan Viswanadhan, Pharm.D., joined Agios as chief strategy and operations officer in March 2025. He is a seasoned biopharmaceutical executive with over 20 years of cross-functional experience advancing novel medicines for patients with serious and life-threatening diseases.

Prior to joining Agios, he served as president and chief operating officer at Be Biopharma, where he led all operational aspects of the company. Before that, he was senior vice president, global cell therapy franchise lead at Bristol Myers Squibb, where he oversaw the integrated cell therapy franchise strategy and led the teams responsible for the development, approval and life cycle management of Breyanzi, a CD19 CAR-T therapy, and Abecma, the first BCMA CAR-T therapy. Earlier in his career, he was vice president, business development and global alliances at Celgene Corporation.

He is a registered pharmacist with a Doctor of Pharmacy degree from Rutgers University and a Master of Business Administration from Cornell University.

Roles

Agios Pharmaceuticals, Inc.

Chief Corporate Development & Strategy Officer · Current role

Mar 2025–present

Be Biopharma

President and Chief Operating Officer · Private biotechnology company.

2021 – 2025

Bristol-Myers Squibb

SVP, Global Cell Therapy · Oversaw development, approval and lifecycle management of Breyanzi and Abecma.

2019 – 2021

Celgene

VP, Business Development and Global Alliances · Managed the portfolio of partnerships and equity investments.

—

Bristol Myers Squibb

Senior Vice President, Global Cell Therapy Franchise Lead · Oversaw integrated cell therapy franchise strategy; led development, approval and life cycle management of Breyanzi and Abecma.

—

Celgene Corporation

Vice President, Business Development and Global Alliances · Managed a portfolio of strategic partnerships and equity investments.

—